Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Colchicine Derivatives Allows Prolonged Survival of Cardiac Allograft in the Rat

백서에서의 동종이형의 심장이식후 Colchicine 변형 물질 투여군의 장기 변존

  • Kim Young-Hak (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Hanyang University) ;
  • Lee Hyung-Chang (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Hanyang University) ;
  • Chung Won-Sang (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Hanyang University) ;
  • Kang Jung-Ho (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Hanyang University) ;
  • Kim Hyuck (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Hanyang University) ;
  • Chon Sun-Ho (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Hanyang University Kuri Hospital) ;
  • Shin Sung-Ho (Department of Thoracic and Cardiovascular Surgery, Asan Medicial Center, University of Ulsan)
  • 김영학 (한양대학교 의과대학 흉부외과학교실) ;
  • 이형창 (한양대학교 의과대학 흉부외과학교실) ;
  • 정원상 (한양대학교 의과대학 흉부외과학교실) ;
  • 강정호 (한양대학교 의과대학 흉부외과학교실) ;
  • 김혁 (한양대학교 의과대학 흉부외과학교실) ;
  • 전순호 (한양대학교 구리병원 흉부외과) ;
  • 신성호 (울산대학교 서울아산병원 흉부외과)
  • Published : 2005.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Colchicine with its immunosupressive properties has been used with benefcial effects in autoimmune disease, such as Gout, etc. Whether colchicine, by virtue of the above property, could attenuate the process of cardiac allograft rejection in the rats is investigated in this report. Material and Method: We compared the untreated group (Control, n=6), Cyclosporin A group (10 mg/kg, daily, n=20), and Colchicine derivative group (Colchicine 40 ${\mu}g$/kg, n=20) of cardiac allografts in the rats. Result: In the untreated control group (n=6), all of 6 rats showed rejection within 3 weeks after cardiac allograft. In the cyclosporin A group (n=20), cyclosporin A (10 mg daily oral dose) was administered at a 10 mg daily oral dose and promoted long-term survival (over 100 days). The cyclosporin A group had one mortality at the 18th post-operative day due to infection. Furthermore, in the Colchicine derivatives group (n=20) with a daily IP (Intra Peritoneum) dose (40 ug/kg/day), we observed long-term survival.(> 100 days), except for one rat that died of an anesthetic problem (respiratory failure) at the 9th post-operative day. Conclusion: Experiments have also been performed to evaluate whether the effect of colchicine derivatives allowed prolonged survival of cardiac allografts compared with the cyclosporin A administration group in the rats.

배경: 콜키신(Colchicine)은 면역 억제 작용을 갖고 있어 자가 면역 질환인 통풍(Gout)등의 질환의 치료제로 이용되어 왔다. 본 연구는 콜키신을 동종이형의 심장이식된 백서에 투여하여 면역억제효과를 확인하고자 하였다. 대상 및 방법: 백서에서의 동종이형 심장이식 거부 반응에 대하여 면역억제제를 투여하지 않는 대조군(Control group)(n=6)과 사이클로스포린(Cyclosporin A) 투여군(n=20), 콜키신 변형물질 투여군(n=20)을 비교함으로써 콜키신의 면역 억제 효과를 비교 검토하였다. 결과: 면역억제제를 투여하지 않은 대조군(n=6)에서는 모두 3주 이내에 거부반응을 보였고, 사이클로스포린(Cyclosporin A) 투여군(n=20)에서는 감염으로 추정되는 한 마리가 술 후 18일째 죽었고, 나머지 19마리는 100일 이상 생존하였다. 또한 콜키신 변형물질 투여군(n=20)에서도 술 후 9일 째에 마취 문제로 인한 호흡부전으로 한 마리가 사망한 외에 나머지는 100일 이상 생존하였다. 결론:본 실험에서는 백서에서의 동종이형 심장 이식 후 현재 면역억제제로 널리 사용되고 있는 Cyclosporin A 투여군과 콜키신 변형물질 투여군을 비교하여 본 바 콜키신 변형 물질 투여군에서도 Cyclosporin A 투여군과 마찬가지로 장기 생존의 결과를 얻을 수 있어 면역 억제 효과가 있음을 알 수 있었다.

Keywords

References

  1. Burke JF Jr, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994;331:358-63 https://doi.org/10.1056/NEJM199408113310604
  2. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Eightyear results of cyclosporin-treated patients with cardiac transplants. J Thorac Cardiovasc Surg 1999;99:500-9
  3. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969;57:225-9
  4. Billingham ME. (Diagnosis of cardiac rejection by) The post-surgical heart. The pathology of cardiac transplantation. Am J Cardiovasc Pathol 1988;1:319-34
  5. Meiser BM, Reichant B. New trends in clinical Immunosuppression. Transplant Proc 1994;13:3181-3
  6. Shumway SJ. Basic immunologic concepts involved in organ transplantation. In: Baumgartner WA, Reitz BA, Achoff SC. Heart & Heart-Lung transplantation. Philadelphia: WB Saunders. 1990;15-24
  7. Morris RE, Wu J, Shorthouse R. A study of the contrastinf effects of cyclosporine, FK506, & rapamycin on suppression of allograft rejection. Transplant Proc 1990;9:1634-41
  8. Young CJ, Sollinger HW. RS61443:A new Immunosuppressive Agent. Transplant Proc 1994;13:3144-6
  9. Kormos RL, Glassman LR, Pham SM, et al. Long-term outcome in a randomized trial of rabbit antithymocyte globulin vs OKT3 immunoprophylaxis. J Heart Lung Transplant 1994;13:S42
  10. Lin HY, Rocher LL, Moquillan MA, Schmaltz S, Pallella TD, Fox IH. Cyclosporin-induced hyperuricemia and gout. New Engl J Med 1989;321:287-92 https://doi.org/10.1056/NEJM198908033210504
  11. Yussim A, Bar-Nathan N, Lustig S, et al. Gastro-intestinal hepatorenal and neuromuscular toxicity caused by cyclosporine- colchicine interaction in renal transplantation. Transplant Proc 1994;13:2825-6
  12. Seidemann P, Fjellner B, Johannessen A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987;14:777-9
  13. Rosenman SJ, Ganji AA, Gallatin WM. Contact dependent redistribution of cell surface adhesion and activation molecules reorganization. FASEB J 1991;5:603
  14. Lyons MJ, Amador R, Petito C, Nagashima K, Weinreb H, Zabriskie JB. Inhibition of acute experimental allergic encephalitis by colchicine. J Exp Med 1986;164:1803-7 https://doi.org/10.1084/jem.164.5.1803
  15. Borisy GG, Taylor EW. The mechanism of action of colchicine- binding of colchine-3H to cellular protein. J Cell Biol 1967;34:533-48
  16. Rosenthal AS, Shevach EM. Function of macrophages in antigen recognition by guinea pig T lymphocytes requirement for histocompatible macrophages and lymphocytes. J Exp Med 1973;138:1194-8 https://doi.org/10.1084/jem.138.5.1194
  17. Freed BM, Lempert N, Lawrence DA, et al. The inhibitory effects of N-ethylmaleimide, colchicine and cytocholasins on human T-cell functions. Int J Immunophamacol 1989;11:459- 65 https://doi.org/10.1016/0192-0561(89)90174-4
  18. Osterman D, Perico N, Imbert O, Barbui C, Bontempelli M, Remuzzi G. Colchicine allows prolonged survival of highly reactive renal allograft in the rat. J Am Soc Nephrol 1993; 4:1294-9